Evidence based medicine
Octreotide Compared With Placebo in a Treatment Strategy for Early Rebleeding in Cirrhosis. A Double Blind,Randomised Pragmatic Trial https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.510280507 Objective: Comparison of Octreotide with placebo in a treatment strategy for Early Rebleeding in Cirrhosis. P- 262 cirrhotic patients after control of acute upper digestive bleeding. I-131 patients were given a randomized, double blind trial of a 15-day course of subcutaneous octreotide vs placebo after control of upper digestive bleeding from any portal hypertensive source in cirrotic patients. C- Early rebleeding, from any source, within 15 days after randomization, was the primary measure of treatment. Secondary measure was the assessment of a 42-day rebleeding rate. O- Octreotide may safely reduce the risk of early rebleeding after upper digestive portal hypertensive hemorrhage in cirrhotic patients treated by Beta- blockers and/or sclerotherapy for long-term prevention of